Document Detail


Ursodeoxycholic acid alone or with chenodeoxycholic acid for dissolution of cholesterol gallstones: a randomized multicentre trial. The British-Italian Gallstone Study group.
MedLine Citation:
PMID:  11136285     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Combination therapy using ursodeoxycholic acid plus chenodeoxycholic acid has been advocated for dissolution of cholesterol gallstones because the two bile acids have complementary effects on biliary lipid metabolism and cholesterol solubilization. AIM: To compare the clinical efficacy of combination therapy with ursodeoxycholic acid monotherapy. PATIENTS AND METHODS: A total of 154 symptomatic patients with radiolucent stones (< or = 15 mm) in functioning gallbladders were enrolled from six centres in England and Italy. They were randomized to either a combination of chenodeoxycholic acid plus ursodeoxycholic acid (5 mg.day/kg each) or to ursodeoxycholic acid alone (10 mg.day/kg). Dissolution was assessed by 6-monthly oral cholecystography and ultrasonography for up to 24 months. RESULTS: Both regimens reduced the frequency of biliary pain and there was no significant difference between them in terms of side-effects or dropout rate. Complete gallstone dissolution on an intention-to-treat basis was similar at all time intervals. At 24 months this was 28% with ursodeoxycholic acid alone and 30% with combination therapy. The mean dissolution rates at 6 and 12 months were 47% and 59% with ursodeoxycholic acid, and 44% and 59% with combination therapy, respectively. CONCLUSION: There is no substantial difference in the efficacy of combined ursodeoxycholic acid and chenodeoxycholic acid and that of ursodeoxycholic acid alone in terms of gallstone dissolution rate, complete gallstone dissolution, or relief of biliary pain.
Authors:
M L Petroni; R P Jazrawi; P Pazzi; A Lanzini; M Zuin; M G Pigozzi; M Fracchia; G Galatola; V Alvisi; K W Heaton; M Podda; T C Northfield
Related Documents :
11503825 - Pamidronic acid and paget's disease: new indication. short-course treatment.
70585 - Dissolution of cholesterol gallstones by ursodeoxycholic acid.
6206835 - Ophthalmic manifestations of infantile phytanic acid storage disease.
15691295 - Long-term ursodeoxycholic acid therapy for primary biliary cirrhosis: a follow-up to 12...
9877125 - Beta 2-microglobulin does not behave as a biological marker of bone remodeling in patie...
2783535 - Pathways mediating crf-induced inhibition of gastric acid secretion in rats.
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Alimentary pharmacology & therapeutics     Volume:  15     ISSN:  0269-2813     ISO Abbreviation:  Aliment. Pharmacol. Ther.     Publication Date:  2001 Jan 
Date Detail:
Created Date:  2001-02-02     Completed Date:  2001-02-02     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8707234     Medline TA:  Aliment Pharmacol Ther     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  123-8     Citation Subset:  IM    
Affiliation:
St. George's Hospital, London, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Chenodeoxycholic Acid / administration & dosage*
Cholelithiasis / drug therapy*
Cholesterol / metabolism*
Drug Therapy, Combination
Female
Humans
Male
Middle Aged
Solubility
Ursodeoxycholic Acid / administration & dosage,  therapeutic use*
Chemical
Reg. No./Substance:
128-13-2/Ursodeoxycholic Acid; 474-25-9/Chenodeoxycholic Acid; 57-88-5/Cholesterol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Oesophageal transit, disintegration and gastric emptying of a film-coated risedronate placebo tablet...
Next Document:  Combination therapy with ribavirin and alpha interferon for the treatment of chronic hepatitis C ref...